Full-Time
Clinical Research Nurse
Celerion
1,001-5,000 employees
Global CRO for early-phase development
No salary listed
Lincoln, NE, USA
In Person
Evening shift; Mon-Sun 1:00 PM–11:30 PM with 1 weekend per month; onsite in Lincoln, NE.
 Biology & Biotech (2) |
|---|
| , |
- current NE RN or LPN license and clinical assessment skills
- strong computer and documentation skills
- perform scheduled events according to the study protocol
- work directly with study managers to successfully ensure a successful trial
- work with participants in the research process, under our care, doing vital sign checks, ECGs, blood draws and telemetry monitoring
- identify and report adverse events to assist in the clinical research process
- availability to work the following scheduling: Mon-Sun from 1300-2330 (clock in from 1300-1500), one weekend (Saturday and Sunday) a month, shifts can be 5x8 or 4x10 based on employee preference
- ACLS certification is a plus
Celerion is a global contract research organization focused on early-phase drug development. It supports pharmaceutical and biotech clients with trial design, feasibility, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs, all conducted under contract. Its work hinges on metabolite profiling using high-resolution mass spectrometry to inform development decisions. With 40+ years of experience and a global, integrated service network, Celerion aims to help clients bring safe, effective treatments to patients faster by delivering rigorous, timely research.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
Simplify's Take
What believers are saying
- THL Partners acquisition in 2026 funds geographic expansion and technology upgrades.
- Jo Goodman’s 29-year expertise from AstraZeneca drives bioanalytical innovation.
- CLIA certification enables high-complexity diagnostic testing on human specimens.
What critics are saying
- Labnotes fails against Veeva, causing client exodus in 12-18 months.
- THL debt strains cash flow, forcing service cuts in 6-12 months.
- CMS revokes CLIA due to Lincoln lab overload in 18-24 months.
What makes Celerion unique
- Celerion excels in HRMS metabolite profiling for early-phase drug development.
- Labnotes software streamlines bioanalytical data management with advanced dataset tools.
- GLP/GCP molecular testing including ELISpot and qPCR accelerates cell/gene therapies.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Celerion who can refer or advise you
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors. The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries
Celerion launches enhanced version of labnotes bioanalytical data Management software.
Celerion was recognized as a CRO Leader in the quality, capabilities and reliability categories across two groups of respondents (small pharma and combined big and small pharma).
Celerion announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.Post this
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory. In her new role, Goodman will oversee the strategic direction and operational performance of the Lincoln bioanalytical laboratory, leveraging her extensive experience in pharmaceutical research and development to drive innovation and design and execute customized bioanalysis for clients’ needs. She will be responsible for delivering on Celerion’s bioanalytical promise of industry-leading science, stringent compliance, and speed of delivery. With over 29 years of experience in the pharmaceutical industry, Goodman brings a wealth of knowledge in regulated GxP and discovery bioanalysis for both in-house and outsourced activities. Prior to joining Celerion, she held positions of increasing responsibility at AstraZeneca, MedImmune, and GlaxoSmithKline. Additionally, Goodman is a recognized thought leader, having recently served as a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Guidance Development and is active in numerous non-profit industry consortia such as EBF, AAPS, and DMDG